88 related articles for article (PubMed ID: 8330463)
1. Multiple-dose phase I study of transnasal butorphanol.
Shyu WC; Pittman KA; Robinson D; Barbhaiya RH
Clin Pharmacol Ther; 1993 Jul; 54(1):34-41. PubMed ID: 8330463
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
Davis GA; Rudy AC; Archer SM; Wermeling DP
Am J Health Syst Pharm; 2004 Feb; 61(3):261-6. PubMed ID: 14986556
[TBL] [Abstract][Full Text] [Related]
3. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
4. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.
Shyu WC; Pittman KA; Robinson DS; Barbhaiya RH
Eur J Clin Pharmacol; 1993; 45(6):559-62. PubMed ID: 8157043
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
Vachharajani NN; Shyu WC; Greene DS; Barbhaiya RH
Biopharm Drug Dispos; 1997 Apr; 18(3):191-202. PubMed ID: 9113342
[TBL] [Abstract][Full Text] [Related]
6. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.
Shyu WC; Morgenthien EA; Pittman KA; Barbhaiya RH
Eur J Clin Pharmacol; 1994; 47(1):57-60. PubMed ID: 7988625
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
Shyu WC; Morgenthien EA; Barbhaiya RH
Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol.
Shyu WC; Mayol RF; Pfeffer M; Pittman KA; Gammans RE; Barbhaiya RH
Biopharm Drug Dispos; 1993 Jul; 14(5):371-9. PubMed ID: 8218955
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH
J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235
[TBL] [Abstract][Full Text] [Related]
10. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of transnasal butorphanol tartrate in postepisiotomy pain: a model to assess analgesia.
Joyce TH; Kubicek MF; Skjonsby BS; Jones MM
Clin Ther; 1993; 15(1):160-7. PubMed ID: 8458045
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
Davis GA; Rudy AIa; Archer SM; Wermeling DP
Am J Health Syst Pharm; 2005 Jan; 62(1):48-53. PubMed ID: 15658072
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis).
Guzman DS; Flammer K; Paul-Murphy JR; Barker SA; Tully TN
J Avian Med Surg; 2011 Sep; 25(3):185-91. PubMed ID: 22216718
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Riggs SM; Hawkins MG; Craigmill AL; Kass PH; Stanley SD; Taylor IT
Am J Vet Res; 2008 May; 69(5):596-603. PubMed ID: 18447789
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration.
Vachharajani NN; Shyu WC; Nichola PS; Boulton DW
Cephalalgia; 2002 May; 22(4):282-7. PubMed ID: 12100090
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
Shyu WC; Barbhaiya RH
Br J Clin Pharmacol; 1996 Oct; 42(4):513-7. PubMed ID: 8904627
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
Vachharajani NN; Shyu WC; Barbhaiya RH
J Clin Pharmacol; 1997 Oct; 37(10):979-85. PubMed ID: 9505990
[TBL] [Abstract][Full Text] [Related]
19. Influence of age on the pharmacokinetics of butorphanol.
Ramsey R; Higbee M; Maesner J; Wood J
Acute Care; 1988; 12 Suppl 1():8-16. PubMed ID: 3344601
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
